Supplements
Top of page
Editorial
India
Apoorva Mandavilli
doi:10.1038/436477a
Top of page
Articles
Then and now-
Inder Verma celebrates the recent success of India's biotechnology industry, applauds the increased investment and looks to the future.
doi:10.1038/436478a
Biotech boom
India's thriving biotechnology industry is threatened by a change in the law. Will the current high levels of investment be enough to secure its future? K. S. Jayaraman finds out.
doi:10.1038/436480a
Vaccines on trial
One of the largest ever vaccine studies is under way in Kolkata. Paroma Basu uncovers the benefits, and difficulties, of inoculating 60,000 people against cholera and typhoid fever.
doi:10.1038/436484a
India's drug tests-
Drug companies are converging on India to conduct low-cost clinical trials. But is it ready to become the outsourcing centre for the world? T. V. Padma investigates.
doi:10.1038/436485a
Ayurveda -
Science and business are racing to tap the 3,000-year-old system of medicine for new drugs, says T. V. Padma.
doi:10.1038/436486a
Breathing life into biology
Mriganka Sur says that life sciences will prosper in India once research and teaching reconnect.
doi:10.1038/436487a
Coming home -
Reagents may be slow to arrive, but the freedom to explore his own research interests more than compensates. Satyajit Mayor is thriving in India.
doi:10.1038/436488a
Rivalry and red tape -
Researchers are suffering as a result of the conflicts between funding agencies. T. V. Padma uncovers plans to heal the rift.
doi:10.1038/436490a
Among the best -
India's life-sciences institutes are rewriting the rule books for research. K. S. Jayaraman finds that they are focusing on higher standards and enterprise.
doi:10.1038/436492a
The coming epidemic -
A staggering 5.1 million people are estimated to be HIV positive in India. Apoorva Mandavilli finds a country on the brink of a crisis.
doi:10.1038/436496a
